Michael K. Ameriks

Michael K. Ameriks

Auto-generated profile, based on publicly available information

Michael K. Ameriks

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BWBrandon A. Wright
Brandon A. Wright
AMAnastassia Matviitsuk
Anastassia Matviitsuk
MBMichael J. Black
Michael J. Black
PGPablo García-Reynaga
Pablo García-Reynaga
LHLuke E. Hanna
Luke E. Hanna
TLTerry P. Lebold
Terry P. Lebold

26 May 2011 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
BTBarry M. Trost
Barry M. Trost
BOBrendan M. O'BOyle
Brendan M. O'BOyle
WTWildeliz Torres
Wildeliz Torres
MAMichael K. Ameriks
Michael K. Ameriks

1 May 2009 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MAMichael K. Ameriks
Michael K. Ameriks
JVJennifer D. Venable
Jennifer D. Venable
In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of inflammatory and autoimmune diseases. All class 1 PI3-kinases (α/β/γ/δ) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis. PI3K δ/γ lipid kinases are mainly restricted to the hematopoetic system whereas PI3Kα/β are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis. Therefore, the challenge in developing a small molecule inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile. Significant advances in the design of such compounds have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kγ in conjunction with pharmacophore modeling and high-throughput screening. Herein, we review the history and challenges involved with the discovery of small molecule isoform-specific PI3K inhibitors. Recent progress in the design of selective PI3Kδ, PI3Kγ, and PI3Kδ/γ dual inhibitors will be presented.

1 July 2010 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MAMichael K. Ameriks
Michael K. Ameriks
SBScott D. Bembenek
Scott D. Bembenek
MBMatthew T. Burdett
Matthew T. Burdett
ICIngrid C. Choong
Ingrid C. Choong
JEJames P. Edwards
James P. Edwards
JZJian Zhu
Jian Zhu

26 December 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
BSBrad M. Savall
Brad M. Savall
DWDongpei Wu
Dongpei Wu
DSDevin M. Swanson
Devin M. Swanson
MSMark Seierstad
Mark Seierstad
NWNyantsz Wu
Nyantsz Wu
MAMichael K. Ameriks
Michael K. Ameriks

1 November 2009 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MAMichael K. Ameriks
Michael K. Ameriks
FAFrank U. Axe
Frank U. Axe
SBScott D. Bembenek
Scott D. Bembenek
JEJames P. Edwards
James P. Edwards
YGYin Gu
Yin Gu
JZJian Zhu
Jian Zhu